Treatment Results of Carcinoma In Situ of the Glottis

Le, Quynh Thu; Takamiya, Robert; Shu, Hui; Smitt, Melanie C.; Singer, Mark M.; Terris, David J.; Fee, Willard E.; Goffinet, Don R.; Fu, Karen K.

doi:10.1001/archotol.126.11.1305

Cited by 34 publications

(25 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Cure rates for CO 2 laser treated patients with early glottic tumors vary from 89% to 100% 4,14,[16][17][18] and are similar to radiotherapy cure rates 19,20 .…”

Section: Introductionmentioning

confidence: 70%

Avaliação da voz em pacientes submetidos à cordectomia com laser de CO2

Haddad

Abrahão

Cervantes

et al. 2006

Rev. Bras. Otorrinolaringol.

View full text Add to dashboard Cite

Aim: To evaluate voice outcomes in patients with early glottic carcinoma treated by CO 2 laser cordectomy. Method: 15 patients with glottic Tis and T1 squamous cell carcinoma treated with CO 2 laser were analyzed. The assessment consisted of perceptual voice analysis, objective voice evaluation and video-laryngo-stroboscopic exam. In addition, patients rated their voices and completed the Voice related Quality of Life (VR-QOL) questionnaire. The results were compared with those obtained in a matched control group. Results: Most of the patients presented some degree of hoarseness on perceptual voice analysis, mainly rough and breathy voices. Their acoustic evaluation compared with the control group showed a small increase in fundamental frequency, but with no statistically significant difference, and the values of jitter, shimmer and noise to harmonic ratio were worse and statistically significant. As regards to videolaryngo-stroboscopic findings, better results were achieved in the less extensive resection group. Patients have had minimal repercussion in their life quality in respect to voice. Conclusions: In spite of voice alterations in patients submitted to cordectomy by CO 2 laser, functional results are acceptable, with minimal repercussion in their quality of life. Avaliação da voz em pacientes submetidos à cordectomia com laser de CO 2 .

show abstract

“…Cure rates for CO 2 laser treated patients with early glottic tumors vary from 89% to 100% 4,14,[16][17][18] and are similar to radiotherapy cure rates 19,20 .…”

Section: Introductionmentioning

confidence: 70%

Avaliação da voz em pacientes submetidos à cordectomia com laser de CO2

Haddad

Abrahão

Cervantes

et al. 2006

Rev. Bras. Otorrinolaringol.

View full text Add to dashboard Cite

show abstract

“…According to Le et al [18] , local recurrence is frequent with stripping alone. In their series of 15 patients treated with vocal cord stripping, 5-and 10-year local control rates were both only 56%.…”

Section: Discussionmentioning

confidence: 99%

“…Each excision can be adapted individually to the size of the tumour allowing the establishment of final diagnosis and therapy at the same time. For glottic CIS, data reported on local control vary between 76 and 100% with larynx preservation in more than 92% of cases [15,16,[18][19][20][21][22][23][24][25] ( table 2 ). In the present series, our data on local control confirm the favourable results obtained in previous studies recommending TLM as the method of choice in cases of glottic CIS when endoscopic exposition poses no greater difficulties to the surgeon.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Transoral Laser Microsurgery for Carcinoma in situ of the Glottic Larynx

Roedel¹,

Christiansen

Mueller³

et al. 2008

ORL

View full text Add to dashboard Cite

Background: To investigate long-term results of transoral CO₂ laser microresection (TLM) in glottic carcinoma in situ (CIS). Methods: A retrospective study of 34 patients with glottic CIS treated initially with TLM between 1986 and 2004. Median post-operative follow-up time was 62 months. Results: Three- and 5-year local control rates were 97 and 93%, respectively. Four patients developed local recurrence (rTis, rTis, rT1, rT4) that could be salvaged by repeated TLM in all cases. Neither adjuvant radiotherapy nor open partial or total laryngectomy was performed. There was no tumour-related death in this series. Conclusion: TLM can be considered as an effective method in the treatment of glottic CIS not only for the primary therapy, but also in cases of local recurrence.

show abstract

“…Higher incidence of local recurrence has been reported after vocal fold stripping, but these can be efficiently managed with repeat surgery especially TOLMS [3]. Involvement of the AC by the disease in Tis is a significant factor for lowering local control [4]. Available expertise plays an important role in deciding the treatment of choice for Tis.…”

Section: Optimal Management Of In Situ Glottic Cancer (Tis)mentioning

confidence: 99%

Optimal Treatment for Early Glottic Carcinoma

Hakeem¹,

Hakeem²,

Wani³

2015

J Oto Rec Surg

View full text Add to dashboard Cite

The management of early glottic cancer has evolved significantly over the past two decades, with transoral laser microsurgery and radiotherapy emerging as the two favored modalities of treatment. Although the role of Open partial conservative surgery has reduced but there are still some specific indications. The preference of one modality over another has generated lot of debate and continues to be controversial. As the survival outcomes are similar in all the modalities, we need to consider factors like professional needs, quality of life, vocal function and cost-effectiveness as regards the modality to be preferred. This manuscript aims at comprehensive overview of the contemporary literature comparing all the treatment modalities.

show abstract

Treatment Results of Carcinoma In Situ of the Glottis

Cited by 34 publications

References 39 publications

Avaliação da voz em pacientes submetidos à cordectomia com laser de CO2

Avaliação da voz em pacientes submetidos à cordectomia com laser de CO2

Transoral Laser Microsurgery for Carcinoma in situ of the Glottic Larynx

Optimal Treatment for Early Glottic Carcinoma

Contact Info

Product

Resources

About